A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials.
Silbert SK, Madan S, Holland EM, Steinberg SM, Little L, Foley T, Epstein M, Sarkisian A, Lee DW, Nikitina E, Kakumanu S, Ruppin E, Shalabi H, Yates B, Shah NN.
Silbert SK, et al. Among authors: madan s.
Blood Adv. 2023 Sep 26;7(18):5566-5578. doi: 10.1182/bloodadvances.2023009789.
Blood Adv. 2023.
PMID: 37486616
Free PMC article.
Clinical Trial.